Form 4: Centessa Pharmaceuticals General Counsel Executes Stock Transactions
SEC Form 4 Filing
Centessa Pharmaceuticals' General Counsel, Iqbal J. Hussain, acquired and disposed of company stock and options, according to a recent SEC filing.
Summary
- Iqbal J. Hussain, General Counsel of Centessa Pharmaceuticals, engaged in multiple transactions involving the company's ordinary shares.
- On December 16, 2024, Hussain acquired 6,000 ordinary shares at a price of $5.84 per share.
- On the same day, Hussain sold 77,705 ordinary shares at a weighted average price of $16.3922, with individual sales ranging from $15.94 to $16.76.
- Following these transactions, Hussain directly owns 125,785 ordinary shares and indirectly owns 5,500 shares through a spouse.
- Hussain also exercised a share option to acquire 6,000 ordinary shares at $5.84 per share.
- The sales were executed under a pre-arranged Rule 10b5-1 trading plan adopted on September 14, 2024.
Sentiment
Score: 5
Explanation: The document is a neutral report of stock transactions by an executive, with no inherent positive or negative sentiment.
Industry Context
This filing is a routine disclosure of insider trading activity, which is common for publicly traded companies. It provides transparency into the transactions of company executives.
Comparison to Industry Standards
- SEC Form 4 filings are standard practice for publicly traded companies in the United States, ensuring transparency of insider transactions.
- The use of a Rule 10b5-1 trading plan is a common method for corporate insiders to manage their stock sales while avoiding accusations of trading on non-public information.
- The reported transactions are typical for executives who hold stock options and shares in their company.
Stakeholder Impact
- The transactions may have a minor impact on the stock price, but are unlikely to significantly affect shareholders.
- The disclosure provides transparency to stakeholders regarding insider trading activity.
Key Dates
| Date | Description |
|---|---|
| 09/14/2024 | Date the Rule 10b5-1 trading plan was adopted by the Reporting Person. |
| 12/16/2024 | Date of the stock acquisition, stock disposal and share option exercise. |
| 12/17/2024 | Date the SEC Form 4 was signed. |
| 02/19/2022 | 25% of the shares subject to the option became exercisable. |
| 02/19/2031 | Expiration date of the share option. |
Keywords
Centessa Pharmaceuticals, insider trading, SEC Form 4, stock transactions, Rule 10b5-1, share options, ordinary shares, Iqbal J. Hussain, General Counsel
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.